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Multiple myeloma relapsing after allogeneic stem cell transplantation (alloSCT) has a poor outcome. To assess
the safety and efﬁcacy of bortezomib and dexamethasone (VD) combination followed by donor lymphocyte
infusions (DLIs) in myeloma patients relapsing or progressing after alloSCT, a prospective phase II study was
designed. The treatment plan consisted of three VD courses followed by escalated doses of DLIs in case of
response or at least stable disease. Nineteen patients were enrolled with a median age of 57 years (range,
33 to 67); 14 patients were allografted from human leukocyte antigeneidentical siblings and 5 from alter-
native donors. Sixteen of 19 patients received the planned treatment, but 3 patients did not: 2 patients
because of disease progression and 1 refused. After the VD phase the response rate was 62%, with 1 complete
remission, 6 very good partial remissions, 5 partial remissions, 2 patients with stable disease, and 5 with
progressive disease. After the DLI phase, the response rate was 68%, but a signiﬁcant upgrade of response was
observed: 3 stringent complete remissions, 2 complete remissions, 5 very good partial remissions, 1 partial
remission, 4 with stable disease, and 1 with progressive disease. With a median follow-up of 40 months
(range, 29 to 68), the 3-year progression-free survival and overall survival rates were 31% and 73%, respec-
tively. Neither unexpected organ toxicities, in particular severe neuropathy, nor severe acute graft-versus-
host disease ﬂares were observed. VD-DLIs is a safe treatment for multiple myeloma patients relapsing or
progressing after alloSCT and may be effective.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
The natural history of multiple myeloma (MM) is char-
acterized by periods of disease control and subsequent
recurrence. Therefore, the use of multiple lines of treatment
is common in the clinical management. Allogeneic stem cell
transplantation (alloSCT) represents an option for young
patients with an available donor; however, a signiﬁcant
fraction of patients relapse [1e4]. Despite the evidence of
long-lasting remissions, myeloablative conditioning regi-
mens have been a matter of concern due to high transplant-
related mortality, sometimes offsetting the survival beneﬁt.
The introduction of reduced intensity and nonmyeloablative
conditioning regimens allowed a toxicity reduction with the
retention of the graft-versus-myeloma (GVM) effect [3e5].
The GVM effect represents an important therapeutic
component of alloSCT; thus, donor lymphocyte infusions
(DLIs) have been used to treat relapse or progression. DLIsedgments on page 428.
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with the most relevant treatment-related morbidity repre-
sented by the occurrence of graft-versus-host disease
(GVHD) (40% to 50%). The use of DLIs at escalating doses
had the most favorable proﬁle in terms of antimyeloma
activity and low incidence of acute GVHD (aGVHD) [7].
Relapse after alloSCT is particularly challenging, because
patients are frequently frail, due to late-onset transplant-
related complications [8], and their disease is often chemo-
resistant [9].
Bortezomib represents an attractive drug for MM treat-
ment after alloSCT, because its toxicity proﬁle does not
overlap with the most common complications occurring
after alloSCT. Bortezomib has been extensively studied in the
context of relapse/progression after autologous SCT, showing
a response rate ranging from 35% [10] to 43% [11]. After
alloSCT, only few data from retrospective studies are
available.
Interestingly, bortezomib has several immune modula-
tory activities. It has been shown to sensitize target cells to
immune-mediated killing through TRAIL/DR5 and Fas/FasL
pathways on natural killer and CD8 T effector cells [12].
Bortezomib treatment can also lead to down-regulation ofTransplantation.
Table 1
Patient Characteristics
Characteristic Value
Age, yr, median % (range) 57 (33e67)
Male 11 (58)
ISS at diagnosis, no. of patients
I 16 (84)
II 2 (10)
III 1 (6)
Lines of treatment before VD-DLI (range) 2 (2e5)
Bortezomib treatment before alloSCT,
no. of patients
4
Previous autologous SCT 19 (100)
Median time from diagnosis to alloSCT,
months (range)
19 (8e52)
Conditioning regimens
TBI 2 Gy based 6 (32)
Thiotepa-ﬂudarabine based 6 (32)
Fludarabine-melphalan based 3 (16)
Busulfan or TBI 9 Gy based 4 (20)
Nonmyeloablative 6 (32)
Reduced intensity 11 (58)
Myeloablative 2 (10)
Donors
HLA-identical siblings 14 (74)
Single antigen mismatched sibling 2 (10)
Matched unrelated donors 3 (16)
GVHD before enrollment
aGVHD 3 (16)
cGVHD 6 (32)
Median time from alloSCT to enrollment,
months (range)
55 (8e145)
Peripheral neuropathy before enrollment,
no. of patients
2 (10, grade 1)
TBI indicates total body irradiation; Gy, Gray.
Values are n (%) unless otherwise noted.
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promoting natural killer activity. Moreover, its direct cyto-
toxic effect may increase the immunogenicity of the dying
cells, resulting in further in vivo expansion of the antitumor
immune response [13,14]. On the other hand, bortezomib can
suppress the immune function by down-regulating pro-
inﬂammatory cytokines, inhibiting dendritic cell maturation
[15], and killing highly activated lymphocytes [16]. Because
there are no prospective studies assessing the efﬁcacy of
bortezomib after alloSCT and considering the GVM associ-
ated with DLI, we conducted a prospective phase II study on
the use of bortezomib and dexamethasone (VD) for myeloma
cytoreduction before DLIs.
METHODS
Study Design
This is a phase II, multicentric, prospective pilot study evaluating the
efﬁcacy and safety of 3 VD courses followed by escalating doses of DLIs in
relapsed or progressing MM. The trial was conducted at four Italian hema-
tology centers between 2007 and 2010. The study was approved by the
ethics committee of all the participating centers and coordinated by the
Fondazione Michelangelo, in accordance with the Declaration of Helsinki
and the Guidelines for Good Clinical Practice. All patients gave informed
consent to the treatment and the analysis of outcome data. The study
was registered to European health authorities with the EudraCT number:
2006-004815-24.
The study enrolled MM patients age 18 to 70 years with measurable
disease relapsing or progressing 100 days after alloSCT and still untreated
for their relapse. For the enrollment the discontinuation of immunosup-
pressive therapy at least 5 weeks before enrollment was required. Patients
were excluded in case of active GVHD or ongoing treatment with immu-
nosuppressive drugs, or if they had contraindications to bortezomib
treatment.
Patients
Nineteen patients with relapsed or progressing MM after alloSCT were
enrolled. Median age was 57 years (range, 33 to 67 years). At diagnosis, 16
patients had International Staging System (ISS) stage I MM, 2 had ISS stage II,
and 1 had ISS stage III MM. Before alloSCT, the median number of previous
lines of treatment was 2 (range, 2 to 5 lines); 4 patients had already received
bortezomib before alloSCT. All patients received a previous autologous SCT.
Median time from diagnosis to alloSCT was 19 months (range, 8 to 52
months). The conditioning regimens were nonmyeloablative in 6, reduced
intensity in 11, and myeloablative in 2 patients. In all cases, peripheral blood
stem cells were infused. Two patients had G1 sensory peripheral neuropathy
at enrollment. Median time between alloSCT and enrollment was 55months
(range, 8 to 145 months). Patient characteristics are summarized in Table 1.
Treatment Plan
Treatment consisted of three 21-day courses with intravenous borte-
zomib 1.3 mg/m2 at days 1, 4, 8, and 11 and oral dexamethasone 20 mg/day
at days 1 to 2, 4 to 5, 8 to 9, and 11 to 12. Fourteen days after the third course
of bortezomib-dexamethasone, in absence of active aGVHD chronic GVHD
(cGVHD), the DLI program was started. DLIs were administered every 6
weeks at escalating cell doses, up to 4 infusions. For transplants from HLA-
identical siblings, the infusions were done at the following cell doses:
5  106 CD3þ/kg, 1 107 CD3þ/kg, 5  107 CD3þ/kg, and 1 108 CD3þ/kg.
For transplants from HLA-mismatched siblings or matched unrelated
donors, the infusion scheme consisted of 5 105 CD3þ/kg, 1106 CD3þ/kg,
5  106 CD3þ/kg, and 1  107 CD3þ/kg. In case of complete remission (CR)
achievement after the VD phase, the patients received only the ﬁrst 2 DLI
doses. The DLI programwas stopped in case of aGVHD or cGVHD occurrence.
All patients received prophylaxis for herpes viruses with valacyclovir
500 mg or 1000 mg twice daily, or with acyclovir 400 mg or 800 mg twice
daily, according to renal function.
Disease Monitoring
Disease response was assessed according to the IMWG criteria [17].
Serum and urine chemistry were evaluated at the following time points: at
enrollment, after each VD, after each DLI, andmonthly after the last DLI for 1
year. Bone marrow biopsy was performed at enrollment, after the VD and
DLI phases, and every 3 months for 1 year after the last DLI. Magnetic
resonance imaging was obtained at enrollment, after the VD and the DLI
phases, and 12 months after the last DLI. X-ray skeletal survey was obtained
at enrollment and at 12 months after the last DLI. Chimerism was assessedon DNA extracted from peripheral blood samples by multiplex ﬂuorescent
short-tandem repeat analysis (AmpFISTR Proﬁler Plus PCR kit, Applied
Biosystems, Foster City, CA). Direct ﬂow cytometric immunophenotyping
was performed to analyze lymphocyte subsets, including CD3þ/CD4þ,
CD3þ/CD8þ, CD20þ, and CD16þ/CD56. All antibodies were obtained from
BD Biosciences (San Jose, CA). Samples were analyzed using the FACSCalibur
ﬂow cytometer (BD Biosciences). Immunophenotyping was performed at
study enrollment, after the VD phase, and at 3, 6, 9, and 12 months after the
last DLI. Molecular minimal residual disease was done on bone marrow
samples as previously described [18] in patients who obtained at least a CR
at the following time points: after the VD and DLI phases, and at 3, 6, 9, and
12 months after the last DLI.Statistics
The primary objective of the study was the efﬁcacy. Secondary objec-
tives were to assess the incidence of aGVHD or cGVHD, the incidence of graft
failure, progression-free survival (PFS), overall survival (OS), and safety.
Enrollment started on January 2007. A planned safety interim analysis
was run by the Independent Review Board on March 2009 after the
enrollment of the ﬁrst 10 patients. There were no unexpected or severe
toxicities. The last patient was enrolled on May 2010. We originally planned
to enroll 25 patients, but due to a slow enrollment rate, mainly caused by
changes in the therapeutic scenario of MM, after 19 patients the study was
closed. Follow-up was updated to August 2012. OS was calculated from the
time of enrollment to death of any cause. PFS was calculated from the day of
enrollment to the day of relapse or progression or death of any cause. The
comparison of PFS according to cGVHD occurrence was calculated from the
day of the ﬁrst DLI. OS and PFS were estimated by Kaplan-Meier method,
and groups were compared by log-rank test. Response duration times were
compared by Welch 2-sample t test. All tests were 2-sided. All the analysis
were carried out using R software, version 2.14.1.RESULTS
Efﬁcacy of Bortezomib-Dexamethasone Followed by DLIs
The median follow-up of alive patients is 40 months
(range, 29 to 68 months). Median duration of the full treat-
ment was 201 days (range, 21 to 401 days). Seventeen of
Figure 1. Upgrade of response between VD and DLI phases.
Figure 2. Progression-free survival curve.
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interrupted the treatment after the ﬁrst VD for disease
progression and 1 after 2 courses for the same reason. The
overall response rate (RR) after the VD phase was 62%: 1 CR
(5%), 6 very good partial remissions (VGPRs) (31%), 5 partial
remissions (PRs) (26%), 2 stable disease (SD) (10%), and 5
progressive disease (PD) (26%) (Figure 1).
Two weeks after the last VD course, 16 patients started
the DLI program and 3 patients did not, 2 because of disease
progression and 1 for refusing to continue treatment. One
patient (6%) received only the ﬁrst DLI due to aGVHD
occurrence. One patient received only the ﬁrst 2 DLIs due to
PD. Six patients received three DLIs, due to PD (2 cases, 12%),
consumption of donor lymphocytes (1 case, 6%), and
achievement of the best response (3 cases, 18%). Eight
patients (50%) received the 4 planned DLIs. The overall RR to
the DLI phase was 68%: 3 stringent CRs (sCRs) (19%), 2 CRs
(13%), 5 VGPRs (31%), 1 PR (6%), 4 SDs (25%), and 1 PD (6%).
The overall RR to the entire programwas 58%: 3 sCRs (16%), 2
CRs (11%), 5 VGPRs (26%), 1 PR (5%), 4 SD (21%), and 4 PDs
(21%) (Figure 1).Figure 3. Overall survival curve.Survival Outcomes
Two- and 3-year PFS rates were 37% and 31%, respectively
(Figure 2, median PFS, 11.9 months). Two- and 3-year OS
rates were 79% and 73%, respectively (Figure 3, median OS
not reached). Although the depth of response to the VD
courses did not translate into a better survival, patients
developing cGVHD after DLI had a superior PFS rate
compared with those without cGVHD (P ¼ .04, median PFS
was 37 versus 8 months after the start of DLI). Two-year PFS
after the start of DLIs was 80% for patients developing cGVHD
compared with 18% for those without it (P ¼ .02). There were
no differences in terms of OS between these 2 groups.
Median response duration to VD plus DLI was 17 months
(range, 4 to 46 months). Patients developing cGVHD had
a median response duration of 29 months (range, 19 to 38
months), which was signiﬁcantly longer (P ¼ .01) than the
one observed in patients without cGVHD (median, 8 months;
range, 4 to 46). There was no signiﬁcant difference in the
duration of response between patients achieving CR or VGPR
after the 3 VD courses compared with those achieving PR or
less (median, 22 months versus 17 months, respectively,
P ¼ .83). Patients achieving sCR, CR, or VGPR after the DLIphase had a longer duration of response than those achieving
PR or less (21 versus 11 months), but this difference was not
statistically signiﬁcant (P ¼ .28), probably due to the limited
number of patients. Median number of lymphocytes infused
was 3  107 CD3þ/kg, and no correlation between T cell dose
and aGVHD or cGVHD occurrence or response was observed.
Median time from alloSCT to relapse was 4.6 years.
Patients relapsed after 4 years post-alloSCT had a better PFS
rate than patients relapsed earlier (not reached versus 7
months, P¼ .077). Median OS of patients relapsed before and
after 4 years post-alloSCT was not reached in both groups.Toxicity Assessment
Bortezomib or dexamethasone dose reductions were
performed in 5 patients (26%) for infections (n ¼ 1), pre-
existent aseptic necrosis of femur (n ¼ 1), and neuropathy
(n ¼ 3). Hematologic toxicities were mild: 2 patients (10%)
experienced grade 2 thrombocytopenia. Six patients (31%)
developed grade 1, 3 (16%) grade 2, and 2 (10%) grade 3
peripheral neuropathy. Six patients (32%) developed grade
Table 2
Adverse Events
Events Grade 1 Grade 2 Grade 3 Grade 4
Thrombocytopenia 1 (5%) 1 (5%)
Peripheral sensory
neuropathy
6 (32%) 3 (16%) 2 (11%)
Neuralgia 5 (26%)
Diarrhea 3 (16%)
Muscle cramps 2 (11%)
Constipation 2 (11%) 1 (5%)
Anorexia 1 (5%)
Infections 6 (32%) 5 (26%) 1 (5%)
Renal failure 1 (5%) 4 (21%)
Asthenia 3 (16%) 2 (11%) 1 (5%)
Rash 4 (21%)
Hypotension 1 (5%)
Dyspnea 2 (11%)
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antiviral prophylaxis, 2 patients developed herpetic infec-
tions, 1 herpes zoster reactivation, and 1 herpetic keratitis. In
2 cases, grade 2 neuropathic pain was associated with
peripheral neuropathy. We did not observe a correlation
involving the elapsed time between suspension of immu-
nosuppression and the beginning of bortezomib and the
appearance of neuropathy. Other toxicities are summarized
in Table 2. After DLIs, 5 patients (31%) developed GVHD: 2
patients had grade I and II aGVHD that evolved to limited
cGVHD and 3 patients had de novo limited cGVHD. Overall, 5
limited cGVHDwere observed, characterized by oral lichen in
3 patients, xerophthalmia in 1 patient, and xerophthalmia
plus lichen in the remaining patient. No patient developed
extensive cGVHD. No post-DLI bone marrow aplasia nor
deaths due to the treatment were observed.Chimerism, Immune Reconstitution, and Minimal
Residual Disease
Donor chimerism at study enrollment was >95% in all
patients, and there were no changes during the treatment.
Mean CD16þ/CD56þ count was 180/mL at study enrollment,
180/mL before DLIs, 140/mL at 3 months after DLIs, and 110/mL
at 12 months after DLIs. This difference was statistically
signiﬁcant (P ¼ .02). No other signiﬁcant differences were
observed. Mean CD3þ/CD4 þ count was 190/mL at study
enrollment, 310/mL before DLIs, 360/mL at 3 months after
DLIs, and 350/mL at 12 months after DLIs. Mean CD3þ/CD8 þ
count was 320/mL at study enrollment, 310/mL before DLIs,
280/mL at 3 months after DLIs, and 330/mL at 12 months after
DLIs. Mean CD19þ count was 170/mL at study enrollment,
120/mL before DLIs, 140/mL at 3 months after DLIs, and 110/mL
at 12 months after DLIs. Bone marrow samples for minimal
residual disease monitoring were available for 5 patients
who achieved at least 1 CR, but in none of these was it
possible to generate the patient-speciﬁc molecular marker.DISCUSSION
Bortezomib is an effective treatment for relapsed
myeloma, but, at present, the data on its use after alloSCT are
few and derived only from retrospective series. We
prospectively evaluated the sequential use of VD and DLIs in
a phase II study including patients relapsing or progressing
after alloSCT. The overall RR following VDs was 62% and after
DLIs was 68% (Figure 1). The 3-year PFS and OS rates were
33% and 78%, respectively. In a retrospective analysis con-
ducted by Hoevenaren and colleagues [19], 30 MM patientsreceived amedian of 4.4 bortezomib courses for persistent or
relapsed disease after alloSCT, and 21 also received escalating
DLIs after the ﬁrst 2 or 3 bortezomib courses. The RR to the
entire treatment was 60%, with a median PFS rate of 12.7
months. The overall RR observed in our and the Hoevenaren
studies are similar and are consistent also with the RR of 61%
of a rather heterogeneous European retrospective analysis on
23 patients [20]. These favorable clinical responses suggest
the existence of a synergistic activity between bortezomib
and the GVM effect. In this sense, preclinical data have
shown that bortezomib has immunomodulatory effects,
through activating TRAIL/DR5-mediated killing [12],
strengthening the natural killer anti-MM activity [13], and
promoting antigen spreading by increasing immunogenicity
of the dying cells [14].
Overall, the DLIs were well tolerated; in particular, we did
not observe an excess of aGVHD and cGVHD, as only 5
patients developed limited cGVHD. DLIs have led to a signif-
icant upgrade of response, in particular in terms of depth of
remission (Figure 1). Although after VD only 1 patient was in
CR and 6 in VGPR, after DLIs 3 patients achieved sCR, 2 CRs,
and 6 VGPRs. This is a remarkable ﬁnding if compared with
DLIs alone, which usually induce responses in the range of
30%, with a low rate of CR [1].
The lack of severe aGVHD exacerbation can be explained
both by the combination with dexamethasone and by the
immunomodulatory properties of bortezomib. Taking
advantage of this property, Koreth et al. designed a reduced-
intensity conditioning regimen including early bortezomib
administration after transplantation, showing promising
results in terms of low incidence of aGVHD and cGVHD and
suggesting that bortezomib is a promising immunomodula-
tory agent in the setting of alloSCT [21,22].
As reported by others [23,24] as well as in our study, we
observed a correlation between cGVHD occurrence and
PFS, supporting the concept that the GVM effect is a key
component of alloSCTandmight be an important component
in long-term disease control. Interestingly, this ﬁnding is in
line with previous studies [25] and supports the hypothesis
that bortezomib may be favorably combined with DLIs. It
should be noted that patients who had a later relapse after
alloSCT responded better to the study treatment, with
a superior PFS. This suggests that an indolent disease facili-
tates the activity of bortezomib and DLIs, because it is well
known that the disease kinetic affects the graft-versus-
tumor efﬁcacy [26].
In our study, toxicities were mild, and no unexpected
grades 3 to 4 side effects were observed. Despite the antiviral
prophylaxis, 2 patients developed herpetic infections: 1
herpes zoster reactivation and 1 herpetic keratitis, empha-
sizing the increased susceptibility of bortezomib-treated
patients to herpetic infections [27] and the necessity of an
adequate prophylaxis. Only 2 patients developed grade 3
peripheral neuropathy. In a previous retrospective study
focused on the incidence of bortezomib-related peripheral
neuropathy, an increased risk of this disabling complication
was observed in alloSCT patients, with 29% of patients
experiencing a grade 3 to 4 neuropathy, and 25% required
bortezomib discontinuation for this problem, despite dose
reduction [28]. In this analysis, a correlation between severe
neurotoxicity and cyclosporine treatment was observed. In
our study, all patients were off treatment by immunosup-
pressive therapy for at least 5 weeks before enrollment and
were therefore protected from any cyclosporine-related
effect on peripheral neuropathy.
V. Montefusco et al. / Biol Blood Marrow Transplant 19 (2013) 424e428428In conclusion, we demonstrated the feasibility of the VD
treatment followed by a program of escalating DLIs. This
combination was safe, well tolerated, may be effective, and
seems to optimize the GVM effect.ACKNOWLEDGMENTS
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